Rockwell Medical is a biopharmaceutical company dedicated to improving patients' lives through effective treatment of iron deficiency and anemia. Our commercially available products include innovative and life-saving treatments for patients with chronic kidney disease who are on dialysis. We are developing a novel therapeutic approach to managing patients with iron deficiency anemia in the rapidly expanding home infusion care setting. Iron is an essential component of cellular function where oxygen is required or energy is produced.
Services
As a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia, the mission of Rockwell Medical is to improve the lives of very sick patients who suffer from the debilitating effects of this disease. Rockwell Medical's vision to establish a new standard of care in iron deficiency and anemia management is built on our novel and differentiated core technology platform, Ferric Pyrophosphate Citrate (FPC). Our initial focus is the treatment of anemia in end-stage renal disease (ESRD).
Rockwell Medical's commitment to improving patient outcomes with innovative drug therapies and high-quality hemodialysis concentrates has driven us to create a strong organization of experienced people in clinical development, manufacturing, distribution, regulatory affairs, sales, and a broad range of other areas.
Mr. Radie has more than three decades of industry experience, working in both public and private pharmaceutical and biotech companies across a range of therapeutic areas. He has held senior executive positions in several companies, including serving as Chief Executive Officer of Zyla Life Sciences, Topaz Pharmaceuticals, Inc., and Transmolecular, Inc.
Rockwell Medical holds its employees, board of directors and officers to the highest standards of personal and professional integrity. We conduct business in compliance with the laws and regulations applicable to our operations and hold our team members accountable to adhere to these requirements. Our Code of Business Conduct and Ethics is intended to promote ethics, integrity and deter inappropriate behavior.
Reviews (1)
Steve Hamrick
Jan 04, 2020
